Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML) : ÆÄÀÌÇÁ¶óÀÎ ¸®ºä

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021

¸®¼­Ä¡»ç Global Markets Direct
¹ßÇàÀÏ 2021³â 12¿ù »óǰÄÚµå 232771
ÆäÀÌÁö Á¤º¸ ¿µ¹® 4011 Pages ¹è¼Û¾È³»
°¡°Ý
US $ 2,500 £Ü 3,185,000 PDF (Single user license) help
1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº Copy & Paste°¡ °¡´ÉÇÕ´Ï´Ù. ÀμâȽ¼ö¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 5,000 £Ü 6,371,000 PDF (Site license) help
µ¿ÀÏ »ç¾÷Àå ³» ¸ðµç ºÐµéÀÌ °øÀ¯ÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ¿ë Àοø¼ö¿¡ Á¦ÇÑÀº ¾ø½À´Ï´Ù. PDF ÆÄÀÏÀº Copy & Paste°¡ °¡´ÉÇÕ´Ï´Ù. PDF ³»ÀÇ ÄÁÅÙÃ÷ Àμâ´Â Á¦ÇÑÀÌ ¾øÀ¸³ª, Àüüº¸°í¼­¿¡ ´ëÇÑ Á¦º»Àº ¿øÄ¢ÀûÀ¸·Î 2ºÎ±îÁö¸¸ Çã¿ëµÇ¸ç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 7,500 £Ü 9,556,000 PDF (Global license) help
µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¼ö¿¡ Á¦ÇÑÀº ¾øÀ¸¸ç, ÇØ¿Ü »ç¾÷Àå ¹× 100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ. PDF ÆÄÀÏÀº Copy & Paste°¡ °¡´ÉÇÕ´Ï´Ù. PDF ³»ÀÇ ÄÁÅÙÃ÷ Àμâ´Â Á¦ÇÑÀÌ ¾øÀ¸³ª, Àüüº¸°í¼­¿¡ ´ëÇÑ Á¦º»Àº ¿øÄ¢ÀûÀ¸·Î 10ºÎ±îÁö¸¸ Çã¿ëµÇ¸ç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.


±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML) : ÆÄÀÌÇÁ¶óÀÎ ¸®ºä Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021
¹ßÇàÀÏ : 2021³â 12¿ù ÆäÀÌÁö Á¤º¸ : ¿µ¹® 4011 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML)Àº ±Þ¼º °ñ¼ö ¾Æ±¸¼º ¹éÇ÷º´À¸·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, Ç÷¾×°ú °ñ¼ö¸¦ ħ¹üÇÏ´Â ÁúȯÀÔ´Ï´Ù. ¹Ì¼÷ÇÑ ¹éÇ÷±¸°¡ °ñ¼ö¿¡ ÃàÀûµÇ¸é¼­ Á¤»óÀûÀÎ Ç÷¾×¼¼Æ÷ÀÇ »ý¼ºÀ» ¹æÇØÇÏ°Ô µË´Ï´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷´Â Ç÷¾× ¼Ó¿¡ µé¾î°¡ Àü½Å¿¡ ÆÛÁý´Ï´Ù. ÁõÈÄ´Â ÇǷΰ¨, ¹ß¿­, ÃâÇ÷, È£Èí°ï¶õ, üÁß °¨¼Ò µîÀÔ´Ï´Ù. °ü·ÃµÈ ¼ÒÀÎÀ¸·Î´Â ¹æ»ç¼±À̳ª È­Çй°Áú ³ëÃâ°ú Èí¿¬ µîÀÌ ÀÖ½À´Ï´Ù. ¾î´À ƯÁ¤ Ç÷¾×Áúȯ ¶§¹®¿¡ AML ÀÌ¿ÜÀÇ Áúȯµµ ¹ßº´ÇÒ ¼ö ÀÖ½À´Ï´Ù. È­Çпä¹ý, ¼öÇ÷, À̽Ä, ¾à¹°¿ä¹ý µîÀÇ Ä¡·á¹ýÀÌ ÀÖ½À´Ï´Ù.

±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML: Acute Myelocytic Leukemia) Ä¡·áÁ¦ °³¹ß ÆÄÀÌÇÁ¶óÀÎ ÇöȲ°ú Ãֽо÷µ¥ÀÌÆ®¿¡ ÀÇÇÑ °¢ °³¹ß ´Ü°è ºñ±³ ºÐ¼®, ±â¾÷À̳ª ¿¬±¸±â°üÀÌ °³¹ßÁßÀÎ Ä¡·áÁ¦, Ä¡·áÁ¦ Æò°¡, ÈÄ±â ´Ü°è ¹× ÁßÁöµÈ ÇÁ·ÎÁ§Æ® °ü·Ã Á¤º¸, ÃֽŠ´º½º¿Í ¹ßÇ¥ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¼­·Ð

±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML, ±Þ¼º°ñ¼ö¾Æ±¸¼º¹éÇ÷º´) °³¿ä

Ä¡·áÁ¦ °³¹ß

±â¾÷¿¡¼­ °³¹ßÁßÀÎ Ä¡·áÁ¦

´ëÇÐ/±â°ü¿¡¼­ ¿¬±¸ÁßÀÎ Ä¡·áÁ¦

ÆÄÀÌÇÁ¶óÀÎ Á¦Ç° °³¿ä

±â¾÷¿¡¼­ °³¹ßÁßÀÎ Á¦Ç°

´ëÇÐ/±â°ü¿¡¼­ ¿¬±¸ÁßÀÎ Á¦Ç°

Ä¡·áÁ¦ °³¹ß¿¡ Âü¿©Çϰí ÀÖ´Â ±â¾÷

Ä¡·áÁ¦ Æò°¡

Ä¡·áÁ¦ °³¿ä

ÈÞÁö »óÅÂÀÎ ÇÁ·ÎÁ§Æ®

°³¹ßÀÌ ÁßÁöµÈ Á¦Ç°

Á¦Ç° °³¹ß ¸¶ÀϽºÅæ

ºÎ·Ï

µµÇ¥

LSH 16.09.30

List of Tables

List of Tables

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, 2021
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drugs In Development, 2021, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 19, 154, 164, 5, 16, 306, 67 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 27, 8, 1, 49 and 29 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodol'ogy
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q